Assessing the Burden of Respiratory Syncytial Virus (RSV)

Abu Dhabi Health Services Company

Status: Not yet enrolling

Conditions: Acute Lower Respiratory Tract Infections; Bronchiolitis; Respiratory Syncytial Virus (RSV) Infection; Pneumonia; Chronic Respiratory Conditions

Study type: Observational

Funder types: Other

Identifiers

NCT07015255

DOH/ADHRTC/2025/361

Details and patient eligibility

About

This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:

• How often does RSV occur
• Who is most at risk
• The long-term and financial effects of RSV

Full description

This study is designed to analyze the impact of Respiratory Syncytial Virus (RSV) across different age groups. It focuses on how often RSV occurs, who is most at risk, and its long-term and financial effects. The study uses existing hospital records from SEHA facilities between January 2018 and December 2024. This is a retrospective observational study, meaning no new tests or treatments are given. Researchers look at medical records from past patients who were diagnosed with RSV. Anonymized data is collected from SEHA's Electronic Medical Records (EMR) and laboratory systems. Only patients with confirmed RSV infections are included.

Enrollment: 1,500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of all ages with a confirmed diagnosis of RSV infection
• Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024
• Patients with documented data in the SEHA electronic medical record (EMR) system

Exclusion criteria

• Patients with suspected RSV infection that is not laboratory-confirmed
• Patients without sufficient data in the SEHA EMR system

Trial design

1,500 participants in 1 patient group

Infants, adults, elderly, and high-risk patients with confirmed RSV infection (2018-2024).

Description:

This retrospective study includes patients of all ages with confirmed Respiratory Syncytial Virus (RSV) infection from January 2018 to December 2024, categorized into four cohorts: (1) Infants and young children, including those with risk factors such as prematurity, low birth weight, and chronic lung or heart disease; (2) Adults aged 18-64 years with or without comorbidities; (3) Elderly adults aged 65 and older, with focus on severe outcomes and mortality; and (4) High-risk individuals across all age groups with underlying conditions such as asthma, COPD, diabetes, immunosuppression, Down syndrome, or cystic fibrosis. No interventions are administered; the study analyzes existing data to assess RSV burden, ICU admissions, long-term health impacts, and associated healthcare costs.